
- December 2011
- Volume 12
- Issue 12
New FDA-Approved Oncology Drugs and Indications, 2011
This chart lists the new FDA-approved oncology drugs of 2011 and indications.
The FDA approved more new oncology drugs in 2011 than it has in a single year in more than a decade, thanks in part to priority review and streamlined evaluation procedures. While this is good news for patients, oncology and hematology specialists must tackle the challenges posed by integrating new therapies into treatment plans.
The chart below lists the new FDA-approved oncology drugs of 2011 and indications.
Chart Key:
*As of December 1, 2011 | Sources: FDA news releases, Drugs@FDA Website, prescribing information for individual drugs
a Drug approved for the first time
b New indication or formulation for previously approved brand-name drug or agent
Articles in this issue
about 14 years ago
Study Supports Smaller Margins in Excising Thicker Melanomasabout 14 years ago
Hematologic Congress Spotlights Major Issues, Emerging Researchabout 14 years ago
Minimally Invasive Surgeries Retain Place in Treatment Planabout 14 years ago
FISH Testing Guides Treatment of CLL: New Drugs on Horizonabout 14 years ago
NICE's Reluctance to Back Yervoy Turns on Cost-Benefit Perceptionsabout 14 years ago
Radium-223 Properties Conducive to mCRPC Careabout 14 years ago
Avastin Increases PFS in Patients With Ovarian Cancerabout 14 years ago
The Year's New Drugs: Integrating Advances of 2011 Into Treatment Plansabout 14 years ago
Overcoming Resistance to Endocrine Therapies


































